ASH 2023: Lymphomas and CLL

CE / CME

Key Studies in Lymphomas and CLL: Independent Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 06, 2024

Expiration: March 05, 2025

Ian Flinn
Ian Flinn, MD, PhD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Ian W. Flinn, MD, PhD, discusses key findings in lymphomas and chronic lymphocytic leukemia (CLL) presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lymphoma or CLL do you provide care for in a typical month?

Which of the following findings was reported at ASH 2023 for the phase III SYMPATICO trial evaluating the addition of venetoclax to ibrutinib compared with placebo + ibrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)?

In the analysis of the phase II ELM-2 study reported at ASH 2023 for the cohort of patients with R/R diffuse large B-cell lymphoma (DLBCL), which of the following most accurately describes the median timing of cytokine-release syndrome (CRS) onset after infusion with the CD3xCD20 bispecific antibody odronextamab?

The phase III SWOG S1826 trial is comparing nivolumab vs brentuximab vedotin (BV) both added to combination chemotherapy consisting of doxorubicin, vinblastine, and dacarbazine (AVD) in patients with newly diagnosed advanced classical Hodgkin lymphoma (cHL). In talking with an older patient about treatment options, which of the following findings would you tell them was reported at ASH 2023 for nivolumab-AVD vs BV-AVD in a subgroup analysis of patients 60 years of age or older?